A 58365 A

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 571139

CAS#: 87896-52-4 (A)

Description: A 58365 A is an angiotensin converting enzyme (ACE) inhibitor isolated from Streptomyces chromofuscus. It is used to treat hypertension and congestive heart failure.


Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-03-29. Prices are subject to change without notice.

A 58365A is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 571139
Name: A 58365 A
CAS#: 87896-52-4 (A)
Chemical Formula: C12H13NO6
Exact Mass: 267.0743
Molecular Weight: 267.24
Elemental Analysis: C, 53.93; H, 4.90; N, 5.24; O, 35.92


Related CAS #: 87896-52-4 (A)   87896-53-5 (B)  

Synonym: A 58365A; A-58365A; A58365A

IUPAC/Chemical Name: 6-Indolizinepropanoic acid, 3-carboxy-1,2,3,5-tetrahydro-8-hydroxy-5-oxo-, (-)-

InChi Key: HMWIHWAAIYAMFZ-UHFFFAOYSA-N

InChi Code: InChI=1S/C12H13NO6/c14-9-5-6(1-4-10(15)16)11(17)13-7(9)2-3-8(13)12(18)19/h5,8,14H,1-4H2,(H,15,16)(H,18,19)

SMILES Code: O=C(O)CCC1=CC(O)=C2CCC(C(O)=O)N2C1=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Vinazzer H, Farine JC. Double-blind cross-over study of the effect of sultosilic acid piperazine salt (A-585) and bezafibrate in primary hyperlipoproteinemia. Atherosclerosis. 1983 Nov;49(2):109-18. PubMed PMID: 6686778.

2: Vinazzer H. [Comparison of the antilipemic effect of bezafibrate with that of piperazine-sultosilate (A 585). A crossed double-blind study]. Wien Klin Wochenschr. 1984 Dec 21;96(24):889-93. German. PubMed PMID: 6152088.

3: Rodríguez L, Demestre I, Sagarra R, Laporte J, Esteve A. [Toxicologic study of piperazine sultosylate (A-585)]. Arch Farmacol Toxicol. 1979 Dec;5(3):281-3.Spanish. PubMed PMID: 546355.

4: Casellas Bernat A, Ribas Grau M, Casellas Bernat G, Riera de Barcia L, Alou Llado M, Solivellas Antich S. [Clinical effectiveness of piperazine sultosylate in the hyperlipidemias]. Rev Clin Esp. 1981 Apr 25;161(1):5-8. Spanish. PubMed PMID: 7255818.

5: Rodríguez L, Roser R, Palacios G, Sagarra R, Esteve A. [Hypolipemic activity of piperazine sultosylate (A-585) in the rat and chicken]. Arch Farmacol Toxicol. 1979 Dec;5(3):272-4. Spanish. PubMed PMID: 546353.

6: Rodríguez L, Parés S, Laporte J, Roser R, Esteve J. [Effect of piperazine sultosylate (A-585) on hypertriglyceridemia induced by ethanol in man]. Arch Farmacol Toxicol. 1979 Dec;5(3):235-7. Spanish. PubMed PMID: 546346.

7: Masana L, Villoria J, Sust M, Ros E, Plana N, Pérez-Jiménez F, Franco M, Oliván JJ, Pintó X, Videla S. Treatment of type IIb familial combined hyperlipidemia with the combination pravastatin-piperazine sultosilate. Eur J Pharmacol. 2004 Aug 2;496(1-3):205-12. PubMed PMID: 15288592.